Jefferies Downgrades Cerevel Therapeutics (CERE) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CERE Hot Sheet
Price: $44.96 --0%
Rating Summary:
5 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Rating Summary:
5 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Join SI Premium – FREE
Jefferies analyst Michael J. Yee downgraded Cerevel Therapeutics (NASDAQ: CERE) from Buy to Hold with a price target of $45.00 (from $40.00).
For an analyst ratings summary and ratings history on Cerevel Therapeutics click here. For more ratings news on Cerevel Therapeutics click here.
Shares of Cerevel Therapeutics closed at $41.39 yesterday.
You May Also Be Interested In
- Essential Properties Realty Trust (EPRT) PT Lowered to $31 at Cantor Fitzgerald
- Hinge Health Inc (HNGE) PT Raised to $135 at Stifel
- BofA Downgrades Marvell (MRVL) to Neutral
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
